Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Date:5/9/2011

Total XIAFLEX Revenue

$12.3$1.3732%Total Worldwide Revenue

$58.4$45.528%Contract Revenues represent amortization of previously received upfront and milestone payments.  XIAFLEX revenue recognition change reflects the one-time recognition of previously deferred revenue upon the Company changing its revenue recognition methodology to record sales of XIAFLEX when units are sold to its distributors rather than when those distributors ship to the physician's office.  

First Quarter 2011 Financial DetailsThe net loss for the first quarter of 2011 was $(11.8) million, or $(0.25) per share, compared to a net loss of $(8.6) million, or $(0.18) per share, reported for the first quarter of 2010.  Net loss for the first quarter of 2011 includes total stock-based compensation expense of $4.3 million, compared to $3.8 million for the first quarter of 2010.

Gross margin on net revenues was 81% for the quarter ended March 31, 2011 compared to 79% for the comparable period in 2010.  Gross margin reflects the costs of products sold, royalty obligations due to the Company's licensors, and the amortization of the deferred costs associated with the Pfizer contract.  The increase in the gross margin rate is due to the contribution of high margin XIAFLEX product sales, including a contribution from the impact of the change in revenue recognition, and year-over-year price increases of Testim in the U.S., partially offset by non recurring favorable Testim product cost adjustments recorded in 2010, and increased managed care rebates.

Investments in research and development for the quarter ended March 31, 2011 were $15.8 million, compared to $8.5 million for the comparable period in 2010.  The increase results principally from the activities related to the phase III XIAFLEX clinical trials for Peyronie's disease, costs incurred to address inspection comments received from European regulators concerning our manufacturing plant
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
6. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
8. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
9. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... could improve the health of your heart, researchers have ... used a standard TENS machine like those designed to ... tragus, the small raised flap at the front of ... , The stimulation changed the influence of the nervous ... that can drive failing hearts too hard. , Professor ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... Aug. 24, 2011 United Therapeutics Corporation (NASDAQ: ... of its FREEDOM-C(2) Phase 3 trial of treprostinil ... formulation of treprostinil, a stable synthetic form of ...  Preliminary analysis demonstrates that the trial did not ...
... Lake, N.Y. New research from the Trudeau Institute ... (LAIV), commonly known as FluMist, elicits protection. The ... Vaccine . The journal article is entitled "Live attenuated ... and was authored by Trudeau Institute scientist Dr. Laura ...
... Mich.---A delicate balance of atomic forces can be exploited ... attribute that,s important for many nanotech applications but hard ... The same type of forces are at work bringing ... supercluster structures in this research are in many ways ...
Cached Biology Technology:FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4Trudeau Institute announces a discovery in how FluMist elicits protection 2Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2
(Date:8/19/2014)... release is available in German . ... inherently intermittent energy sources. If a large amount of electricity ... future, excess energy will have to be stored during productive ... existing storage capacities are far from adequate for the purpose. ... One important focus lies on battery systems that used to ...
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s not ... the Philippine tarsier: a tiny, adorable and downright "cool" primate ... that Americans are familiar with," said Rafe Brown, curator-in-charge at ... eyes and ears; an extremely cute, furry body; a long ... expanded fingers and toe tips that look a bit like ...
(Date:8/19/2014)... purchased at retail seafood counters in 10 different ... expose consumers to unexpectedly high levels of mercury, ... present a fish of the same species, but ... mislabeling offense, according to new research by University ... of seafood is essential to allow consumers to ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... FL (May 21, 2010).The University of Miami (UM) has ... the Howard Hughes Medical Institute (HHMI) to strengthen the ... and Sciences, where the program resides, will use the ... from groups traditionally underrepresented in the sciences to pursue ...
... at the University of Oxford and Royal Holloway University of London ... Bt works best if applied to young plants and ... is published today (20 May) in the open-access journal PLoS ... Bacillus thuringiensis is a common method for controlling a ...
... -- At a recent Specialty Coffee Association of America ... to increase the overall quality and availability of specialty ... new effort, called the Global Coffee Quality Research Initiative ... coffee roasters and agricultural researchers in partnership with the ...
Cached Biology News:UM receives 5th consecutive Howard Hughes Medical Institute grant for science education 2Study uncovers optimal ecology of bioinsecticide 2New global coffee research initiative announced 2New global coffee research initiative announced 3
... DNA Engine Opticon 2 real-time PCR detection ... for fluorescence excitation (470-505 nm) and two ... 540-700 nm). The Opticon 2 system is ... which includes a thermal gradient feature. This ...
Fingerprinting II Informatix cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to ...
... II Informatix dimensioning ... optional module that ... analysis, multidimensional scaling, ... MANOVA, and self-organizing ...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Biology Products: